These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

398 related articles for article (PubMed ID: 11016652)

  • 1. Defining promiscuous MHC class II helper T-cell epitopes for the HER2/neu tumor antigen.
    Kobayashi H; Wood M; Song Y; Appella E; Celis E
    Cancer Res; 2000 Sep; 60(18):5228-36. PubMed ID: 11016652
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of helper T-cell epitopes that encompass or lie proximal to cytotoxic T-cell epitopes in the gp100 melanoma tumor antigen.
    Kobayashi H; Lu J; Celis E
    Cancer Res; 2001 Oct; 61(20):7577-84. PubMed ID: 11606397
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Defining MHC class II T helper epitopes for WT1 tumor antigen.
    Kobayashi H; Nagato T; Aoki N; Sato K; Kimura S; Tateno M; Celis E
    Cancer Immunol Immunother; 2006 Jul; 55(7):850-60. PubMed ID: 16220325
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peptide HER2(776-788) represents a naturally processed broad MHC class II-restricted T cell epitope.
    Sotiriadou R; Perez SA; Gritzapis AD; Sotiropoulou PA; Echner H; Heinzel S; Mamalaki A; Pawelec G; Voelter W; Baxevanis CN; Papamichail M
    Br J Cancer; 2001 Nov; 85(10):1527-34. PubMed ID: 11720440
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of an antigenic epitope for helper T lymphocytes from carcinoembryonic antigen.
    Kobayashi H; Omiya R; Ruiz M; Huarte E; Sarobe P; Lasarte JJ; Herraiz M; Sangro B; Prieto J; Borras-Cuesta F; Celis E
    Clin Cancer Res; 2002 Oct; 8(10):3219-25. PubMed ID: 12374692
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recognition of prostate and melanoma tumor cells by six-transmembrane epithelial antigen of prostate-specific helper T lymphocytes in a human leukocyte antigen class II-restricted manner.
    Kobayashi H; Nagato T; Sato K; Aoki N; Kimura S; Murakami M; Iizuka H; Azumi M; Kakizaki H; Tateno M; Celis E
    Cancer Res; 2007 Jun; 67(11):5498-504. PubMed ID: 17545632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor-reactive T helper lymphocytes recognize a promiscuous MAGE-A3 epitope presented by various major histocompatibility complex class II alleles.
    Kobayashi H; Song Y; Hoon DS; Appella E; Celis E
    Cancer Res; 2001 Jun; 61(12):4773-8. PubMed ID: 11406551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel strategy for the discovery of MHC class II-restricted tumor antigens: identification of a melanotransferrin helper T-cell epitope.
    Röhn TA; Reitz A; Paschen A; Nguyen XD; Schadendorf D; Vogt AB; Kropshofer H
    Cancer Res; 2005 Nov; 65(21):10068-78. PubMed ID: 16267033
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A HER2/NEU-derived peptide, a K(d)-restricted murine tumor rejection antigen, induces HER2-specific HLA-A2402-restricted CD8(+) cytotoxic T lymphocytes.
    Ikuta Y; Okugawa T; Furugen R; Nagata Y; Takahashi Y; Wang L; Ikeda H; Watanabe M; Imai S; Shiku H
    Int J Cancer; 2000 Aug; 87(4):553-8. PubMed ID: 10918197
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EGFR inhibitors augment antitumour helper T-cell responses of HER family-specific immunotherapy.
    Kumai T; Matsuda Y; Oikawa K; Aoki N; Kimura S; Harabuchi Y; Celis E; Kobayashi H
    Br J Cancer; 2013 Oct; 109(8):2155-66. PubMed ID: 24045666
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ii-Key/HER-2/neu(776-790) hybrid peptides induce more effective immunological responses over the native peptide in lymphocyte cultures from patients with HER-2/neu+ tumors.
    Sotiriadou NN; Kallinteris NL; Gritzapis AD; Voutsas IF; Papamichail M; von Hofe E; Humphreys RE; Pavlis T; Perez SA; Baxevanis CN
    Cancer Immunol Immunother; 2007 May; 56(5):601-13. PubMed ID: 16960693
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of HLA DR7-restricted epitopes from human telomerase reverse transcriptase recognized by CD4+ T-helper cells.
    Schroers R; Huang XF; Hammer J; Zhang J; Chen SY
    Cancer Res; 2002 May; 62(9):2600-5. PubMed ID: 11980655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potent CD4+ T-cell epitope P30 enhances HER2/neu-engineered dendritic cell-induced immunity against Tg1-1 breast cancer in transgenic FVBneuN mice by enhanced CD4+ T-cell-stimulated CTL responses.
    Xie Y; Chen Y; Ahmed KA; Li W; Ahmed S; Sami A; Chibbar R; Tang X; Tao M; Xu J; Xiang J
    Cancer Gene Ther; 2013 Oct; 20(10):590-8. PubMed ID: 24052129
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NY-ESO-1 119-143 is a promiscuous major histocompatibility complex class II T-helper epitope recognized by Th1- and Th2-type tumor-reactive CD4+ T cells.
    Zarour HM; Maillere B; Brusic V; Coval K; Williams E; Pouvelle-Moratille S; Castelli F; Land S; Bennouna J; Logan T; Kirkwood JM
    Cancer Res; 2002 Jan; 62(1):213-8. PubMed ID: 11782380
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Establishment of HLA-DR4 transgenic mice for the identification of CD4+ T cell epitopes of tumor-associated antigens.
    Yatsuda J; Irie A; Harada K; Michibata Y; Tsukamoto H; Senju S; Tomita Y; Yuno A; Hirayama M; Abu Sayem M; Takeda N; Shibuya I; Sogo S; Fujiki F; Sugiyama H; Eto M; Nishimura Y
    PLoS One; 2013; 8(12):e84908. PubMed ID: 24386437
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of promiscuous KIF20A long peptides bearing both CD4+ and CD8+ T-cell epitopes: KIF20A-specific CD4+ T-cell immunity in patients with malignant tumor.
    Tomita Y; Yuno A; Tsukamoto H; Senju S; Kuroda Y; Hirayama M; Irie A; Kawahara K; Yatsuda J; Hamada A; Jono H; Yoshida K; Tsunoda T; Kohrogi H; Yoshitake Y; Nakamura Y; Shinohara M; Nishimura Y
    Clin Cancer Res; 2013 Aug; 19(16):4508-20. PubMed ID: 23714729
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of a MHC class-II restricted epitope in carcinoembryonic antigen.
    Shen L; Schroers R; Hammer J; Huang XF; Chen SY
    Cancer Immunol Immunother; 2004 May; 53(5):391-403. PubMed ID: 14624313
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of a promiscuous HLA DR-restricted T-cell epitope derived from the inhibitor of apoptosis protein survivin.
    Piesche M; Hildebrandt Y; Zettl F; Chapuy B; Schmitz M; Wulf G; Trümper L; Schroers R
    Hum Immunol; 2007 Jul; 68(7):572-6. PubMed ID: 17584578
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of EBV-latent membrane protein 1-specific MHC class II-restricted T-cell responses against natural killer lymphoma cells.
    Kobayashi H; Nagato T; Takahara M; Sato K; Kimura S; Aoki N; Azumi M; Tateno M; Harabuchi Y; Celis E
    Cancer Res; 2008 Feb; 68(3):901-8. PubMed ID: 18245493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The HER2/neu-derived peptide p654-662 is a tumor-associated antigen in human pancreatic cancer recognized by cytotoxic T lymphocytes.
    Peiper M; Goedegebuure PS; Linehan DC; Ganguly E; Douville CC; Eberlein TJ
    Eur J Immunol; 1997 May; 27(5):1115-23. PubMed ID: 9174600
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.